NCT00392912View on ClinicalTrials.gov

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

July 31, 2010

Conditions
Alzheimer's DiseaseHypogonadism
Interventions
DRUG

AndroGel (Solvay Pharmaceuticals)

Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.

Trial Locations (1)

77030

Michael E. DeBakey VA Medical Center, Houston

All Listed Sponsors
collaborator

Solvay Pharmaceuticals

INDUSTRY

lead

Michael E. DeBakey VA Medical Center

FED

NCT00392912 - Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone | Biotech Hunter | Biotech Hunter